The CD8+ tumor-infiltrating lymphocytes repress tumors in a cytotoxic manner and are reported to affect prognosis, immunotherapy response, and survival outcomes in colorectal cancer (CRC) patients (8). This evidence concerns the gene CD8A and neoplasm.